 SAN DIEGO, July 30, 2021 PRNewswire -- NuVasive, Inc. NASDAQ: NUVA, the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that it received its latest U.S. Food and Drug Administration 510k clearance for the Pulse platform, after receiving CE certification earlier this summer. In addition, the Company announced the commercial launch of Pulse which is now available for sale in targeted global regions. 